• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

    1.395 +0.035 (+2.57%)
    Streaming Delayed Price Updated: 12:23 PM EDT, Apr 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 250,052
    Open 1.370
    Bid (Size) 1.390 (300)
    Ask (Size) 1.400 (2,100)
    Prev. Close 1.360
    Today's Range 1.340 - 1.430
    52wk Range 0.8800 - 1.710
    Shares Outstanding 65,352,279
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Positive Results on MAVERIC Phase III Trial and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
    Via Get News
    Topics Intellectual Property
    News headline image
    $30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
    Via Get News
    Topics Intellectual Property

    Performance

    YTD
    +40.3%
    +40.3%
    1 Month
    +32.9%
    +32.9%
    3 Month
    +34.1%
    +34.1%
    6 Month
    +19.2%
    +19.2%
    1 Year
    +29.2%
    +29.2%

    More News

    Read More
    On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
    Via Chartmill
    News headline image
    New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
    Via PressReach
    News headline image
    Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today ↗
    Via Benzinga
    News headline image
    New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
    Via Newsfile
    News headline image
    Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
    Via PressReach
    News headline image
    This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
    Via Benzinga
    News headline image
    Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
    Via Newsfile
    News headline image
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options
    Via Investor Brand Network
    News headline image
    Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart
    Via Newsfile
    News headline image
    “Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”
    Via AB Newswire
    News headline image
    3 Penny Stocks Ready to Break Out in 2025
    Via MarketBeat
    News headline image
    Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!
    Via AB Newswire
    News headline image
    “Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
    Via AB Newswire
    Topics Economy
    News headline image
    Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
    Via AB Newswire
    News headline image
    CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study ↗
    Via Benzinga
    News headline image
    Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
    Via AB Newswire
    News headline image
    Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
    Via Newsfile
    News headline image
    “Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
    Via AB Newswire
    Topics Electric Vehicles
    Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
    Via AB Newswire
    “Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
    Via AB Newswire
    Topics Government
    “Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
    Via AB Newswire
    Topics Artificial Intelligence
    Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
    Via AB Newswire
    Topics Intellectual Property
    Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
    Via AB Newswire

    Frequently Asked Questions

    Is Cardiol Therapeutics Inc. - Class A Common Shares publicly traded?
    Yes, Cardiol Therapeutics Inc. - Class A Common Shares is publicly traded.
    What exchange does Cardiol Therapeutics Inc. - Class A Common Shares trade on?
    Cardiol Therapeutics Inc. - Class A Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Cardiol Therapeutics Inc. - Class A Common Shares?
    The ticker symbol for Cardiol Therapeutics Inc. - Class A Common Shares is CRDL on the Nasdaq Stock Market
    What is the current price of Cardiol Therapeutics Inc. - Class A Common Shares?
    The current price of Cardiol Therapeutics Inc. - Class A Common Shares is 1.395
    When was Cardiol Therapeutics Inc. - Class A Common Shares last traded?
    The last trade of Cardiol Therapeutics Inc. - Class A Common Shares was at 04/24/26 12:23 PM ET
    What is the market capitalization of Cardiol Therapeutics Inc. - Class A Common Shares?
    The market capitalization of Cardiol Therapeutics Inc. - Class A Common Shares is 91.17M
    How many shares of Cardiol Therapeutics Inc. - Class A Common Shares are outstanding?
    Cardiol Therapeutics Inc. - Class A Common Shares has 91M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.